Hyperbaric oxygen therapy increases norepinephrine levels for the treatment of Parkinson’s Disease

Tissue concentrations of norepinephrine (NE) are markedly decreased in various regions of the brain in Parkinson patients. Not only is NE involved in cognitive operations, “freezing” of gait, tremor, dyskinesia, REM sleep regulation, and other aspects of brain function, but evidence also suggest its role in the neurodegenerative process itself. This study discusses the ability of hyperbaric oxygen therapy to help increase NE levels in the brain; thereby, helping to restore motor deficits in Parkinson’s disease patients <view study>

Previous
Previous

Parkinson progression reduced by mild hyperbaric oxygen therapy

Next
Next

Hyperbaric oxygen therapy reduces bone loss associated with osteoclasts